1. Signaling Pathways
  2. Cell Cycle/DNA Damage
  3. CDK
  4. CDK8 Isoform

CDK8

Cyclin-dependent kinase 8 is a member of the cyclin-dependent protein kinase (CDK) family. CDK8 and cyclin C associate with the mediator complex and regulate transcription by several mechanisms. CDK8 binds to and/or phosphorylates several transcription factors, which can have an activating or inhibitory effect on transcription factor function. CDK8 phosphorylates the Notch intracellular domain, SREBP, and STAT1 S727. CDK8 also inhibits transcriptional activation by influencing turnover of subunits in the mediator complex tail module. In addition, CDK8 influences binding of RNA polymerase II to the mediator complex.

CDK8 Related Products (24):

Cat. No. Product Name Effect Purity
  • HY-N0400
    Wogonin
    Inhibitor 99.98%
    Wogonin is a naturally occurring mono-flavonoid, can inhibit the activity of CDK8 and Wnt, and exhibits anti-inflammatory and anti-tumor effects.
  • HY-111388A
    SEL120-34A monohydrochloride
    Inhibitor 98.69%
    SEL120-34A monohydrochloride is an ATP-competitive and selective CDK8 inhibitor, inhibits kinase activities of CDK8/CycC and CDK19/CycC complexes with IC50s of 4.4 nM and 10.4 nM, respectively, with a Kd of 3 nM for CDK8.
  • HY-120350
    BI-1347
    Inhibitor 98.95%
    BI-1347 is an orally active, selective and potent CDK8 inhibitor (IC50=1.1 nM).
  • HY-19984
    CCT-251921
    Inhibitor 98.86%
    CCT-251921 is a potent, selective, and orally bioavailable CDK8 inhibitor with an IC50 of 2.3 nM.
  • HY-126675A
    AS2863619
    Inhibitor ≥98.0%
    AS2863619 enables conversion of antigen-specific effector/memory T cells into Foxp3+ regulatory T (Treg) cells for the treatment of various immunological diseases.
  • HY-143889
    Senexin C
    Inhibitor
    Senexin C is a selective and orally active CDK8/19 inhibitor.
  • HY-151371
    CDK8-IN-10
    Inhibitor
    CDK8-IN-10 (compound 2) is a potent, selective cyclin-dependent kinase (CDK8) inhibitor with an IC50 value of 8.25 nM.
  • HY-151463
    CDK8-IN-11
    Inhibitor
    CDK8-IN-11 is a potent and selective CDK8 inhibitor with an IC50 value of 46 nM.
  • HY-15681
    Senexin A
    Inhibitor 99.85%
    Senexin A is a CDK8 inhibitor with an IC50 of 280 nM.
  • HY-101611
    MSC2530818
    Inhibitor 99.69%
    MSC2530818 is a potent, selective and orally available CDK8 inhibitor with an IC50 of 2.6 nM for CDK8.
  • HY-111518
    JH-XI-10-02
    Inhibitor 98.18%
    JH-XI-10-02 is a PROTAC connected by ligands for Cereblon and CDK.
  • HY-12293
    LY2857785
    Inhibitor 98.88%
    LY2857785 is a type I reversible and competitive ATP kinase inhibitor against CDK9 (IC50 11 nM) and other transcription kinases CDK8 (IC50 16 nM), and CDK7 (IC50 246 nM).
  • HY-12280
    THZ2
    Inhibitor 99.62%
    THZ2 is a potent and selective CDK7 inhibitor with an IC50 of 13.9 nM.
  • HY-122586
    BRD6989
    Inhibitor 99.85%
    BRD6989, an analog of the natural product cortistatin A (dCA), inhibits CDK8 and upregulates IL-10.
  • HY-126675
    AS2863619 free base
    Inhibitor ≥98.0%
    AS2863619 free base enables conversion of antigen-specific effector/memory T cells into Foxp3+ regulatory T (Treg) cells for the treatment of various immunological diseases.
  • HY-145121
    DS96432529
    Inhibitor 99.79%
    DS96432529 is a potent and orally active bone anabolic agent through CDK8 inhibition.
  • HY-111388B
    SEL120-34A HCl
    Inhibitor 99.98%
    SEL120-34A HCl is a potent, selective, orally available, ATP-competitive CDK8 inhibitor, with IC50s of 4.4 nM and 10.4 nM for CDK8/CycC and CDK19/CycC, respectively, with antitumor activity.
  • HY-139875
    JH-XVI-178
    Inhibitor 98.16%
    JH-XVI-178 is a highly potent and selective inhibitor of CDK8/19 that displays low clearance and moderate oral pharmacokinetic properties.
  • HY-103492
    CDK8-IN-1
    Inhibitor 99.77%
    CDK8-IN-1 is a potent and selective CDK8 inhibitor with an IC50 of 3 nM.
  • HY-111388
    SEL120-34A
    Inhibitor
    SEL120-34A is a potent, selective, orally available, ATP-competitive CDK8 inhibitor, with IC50s of 4.4 nM and 10.4 nM for CDK8/CycC and CDK19/CycC, respectively, with antitumor activity.